Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 1,453,049 |
|
|||||
| News | - | ||||||
| Day High | 6.16 | Low High |
|||||
| Day Low | 5.76 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Pulmonx Corporation | LUNG | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.485 | -7.75% | 5.77 | 17:39:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.15 | 5.76 | 6.16 | 5.77 | 6.255 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,419 | 1,453,049 | $ 5.90 | $ 8,578,907 | - | 5.76 - 14.92 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:29:35 | 25 | $ 5.94 | USD |
Pulmonx Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 222.75M | 38.54M | - | 68.68M | -60.84M | -1.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Pulmonx News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LUNG Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.01 | 7.31 | 5.76 | 6.63 | 272,503 | -1.24 | -17.69% |
| 1 Month | 9.09 | 9.14 | 5.76 | 7.34 | 336,112 | -3.32 | -36.52% |
| 3 Months | 9.36 | 10.01 | 5.76 | 8.20 | 484,917 | -3.59 | -38.35% |
| 6 Months | 12.78 | 14.92 | 5.76 | 9.91 | 468,025 | -7.01 | -54.85% |
| 1 Year | 12.95 | 14.92 | 5.76 | 10.34 | 349,918 | -7.18 | -55.44% |
| 3 Years | 44.67 | 45.81 | 4.07 | 17.62 | 410,521 | -38.90 | -87.08% |
| 5 Years | 38.00 | 69.4779 | 4.07 | 22.19 | 391,027 | -32.23 | -84.82% |
Pulmonx Description
| Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets. |
